Browsing by Author "Suárez Rodríguez, Cristina"
Now showing items 1-12 of 12
-
Advanced Prostate Cancer with ATM Loss: PARP and ATR Inhibitors
Neeb, Antje; Herranz Martín, Nicolás; Arce Gallego, Sara; Buroni, Lorenzo; Yuan, Wei; Athie Cuervo, Alejandro; Casals, Teresa; Casanova Salas, Irene; Cordoba, Sarai; Castro, Natalia; González Rodríguez, Macarena; Morales Barrera, Rafael; Suárez Rodríguez, Cristina; Carles Galceran, Joan; Serra Elizalde, Violeta; Mateo Valderrama, Joaquim; Miranda, Susana (Elsevier, 2021-02) -
Cell Plasticity-Related Phenotypes and Taxanes Resistance in Castration-Resistant Prostate Cancer
Jiménez, Natalia; Reig, Òscar; Montalbo, Ruth; Milà-Guasch, Maria; Nadal-Dieste, Lluis; Castellano, Giancarlo; Carles Galceran, Joan; Suárez Rodríguez, Cristina (Frontiers Media, 2020-11-02) -
Grade 3/4 Adverse Event Costs of Immuno-oncology Combination Therapies for Previously Untreated Advanced Renal Cell Carcinoma
Geynisman, Daniel M.; Burotto, Mauricio; Suárez Rodríguez, Cristina; Bourlon, Maria T.; Porta, Camillo; McGregor, Bradley (Oxford University Press, 2023-01) -
Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma
Ernst, Matthew; Yuasa, Takeshi; Takemura, Kosuke; Suárez Rodríguez, Cristina; Navani, Vishal; Wells, Connor; Donskov, Frede (American Medical Association, 2022-06-01) -
Kidney cancer PDOXs reveal patient-specific pro-malignant effects of antiangiogenics and its molecular traits
Moserle, Lidia; Pons, Roser; Martínez-Lozano, Mar; Jiménez-Valerio, Gabriela A; Vidal, August; Suárez Rodríguez, Cristina; Trilla Herrera, Enric; Jiménez Flores, José Antonio; Torres Ramirez, Inés de; Carles Galceran, Joan (Wiley, 2020-12-07) -
Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma
McDermott, David F.; Lee, Jae-Lyun; Ziobro, Marek; Suárez Rodríguez, Cristina; Langiewicz, Przemyslaw; Matveev, Vsevolod Borisovich (American Society of Clinical Oncology, 2021-03-20) -
Phase 1b/2a study of galunisertib, a small molecule inhibitor of transforming growth factor-beta receptor I, in combination with standard temozolomide-based radiochemotherapy in patients with newly diagnosed malignant glioma
Wick, Antje; Desjardins, Annick; Suárez Rodríguez, Cristina; Forsyth, Peter; Gueorguieva, Ivelina; Burkholder, Tiana; Rodon Ahnert, Jordi (Springer, 2020-10) -
Randomized Phase II Trial of Sapanisertib ± TAK-117 vs. Everolimus in Patients With Advanced Renal Cell Carcinoma After VEGF-Targeted Therapy
Choueiri, T.; Suárez Rodríguez, Cristina; Hainsworth, John; Voog, Eric; Duran, Ignacio; Porta, Camillo (Oxford University Press, 2022-12) -
Results from a First-in-Human Phase I Study of Siremadlin (HDM201) in Patients with Advanced Wild-Type TP53 Solid Tumors and Acute Leukemia
Stein, Eytan M.; DeAngelo, Daniel; Chromik, Jörg; Chatterjee, Manik; Bauer, Sebastian; Lin, Chia-Chi; Suárez Rodríguez, Cristina; Carpio Segura, Cecilia Carmen (American Association for Cancer Research, 2023-03-01) -
SEOM clinical guideline for treatment of kidney cancer (2019)
Pérez-Valderrama, Begoña; Suárez Rodríguez, Cristina; de‑Velasco, G.; Beato, C.; Chirivella, I.; Lázaro, Martín (Springer, 2020-02) -
Temporal Trends in Grade 3/4 Adverse Events and Associated Costs of Nivolumab Plus Cabozantinib Versus Sunitinib for Previously Untreated Advanced Renal Cell Carcinoma
Geynisman, Daniel M.; Burotto, Mauricio; Suárez Rodríguez, Cristina; Bourlon, Maria T.; Huo, Stephen; Porta, Camillo (Springer, 2022-07) -
Update in collecting duct carcinoma: Current aspects of the clinical and molecular characterization of an orphan disease
Suárez Rodríguez, Cristina; Marmolejo Castañeda, David; Valdivia Bustamante, Augusto Alejandro; Morales Barrera, Rafael; González Rodríguez, Macarena; Mateo Valderrama, Joaquim; Semidey Raven, Maria Eugenia; Lorente García, David; Trilla Herrera, Enric; Carles Galceran, Joan (Frontiers Media, 2022-10-04)